Siemens Healthineers AG (OTCMKTS:SMMNY) Receives Consensus Rating of “Buy” from Analysts

Siemens Healthineers AG (OTCMKTS:SMMNY) has earned a consensus rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and three have given a strong buy rating to the company.

Several research analysts have issued reports on the company. Royal Bank Of Canada started coverage on Siemens Healthineers in a research note on Wednesday, December 17th. They set a “moderate buy” rating for the company. Deutsche Bank Aktiengesellschaft cut shares of Siemens Healthineers from a “buy” rating to a “hold” rating in a research report on Thursday, December 4th. Finally, Zacks Research lowered shares of Siemens Healthineers from a “hold” rating to a “strong sell” rating in a research report on Friday, December 12th.

Siemens Healthineers Price Performance

Shares of SMMNY opened at $27.04 on Friday. Siemens Healthineers has a 1 year low of $23.28 and a 1 year high of $30.19. The stock has a 50 day simple moving average of $25.58 and a 200-day simple moving average of $26.86.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.